Auxilium's Xiaflex shows positive Phase 4 results Auxilium announced interim data from its Phase 4 retreatment study evaluating Xiaflex in adult patients with Dupuytren's contracture and a recurrent contracture with a palpable cord. Xiaflexis a biologic approved in the U.S., EU, Canada and Australia for the treatment of adult DC patients with a palpable cord, and has been granted Orphan Drug Designation in the U.S. by the FDA. 87% of recurrent contractures of metacarpophalangeal joints were successfully retreated. Patients showed an average 83% improvement in fixed flexion. 85% of recurrent contractures of proximal interphalangeal were successfully retreated. Retreatment with CCH was well tolerated.